Department of Hematology, the First Affiliated Hospital of Sun Yat-Sen University, 510080 Guangzhou, Guangdong, China.
Diagn Pathol. 2014 Mar 29;9:76. doi: 10.1186/1746-1596-9-76.
Aberrant expression of miRNA (miR)-96 is associated with tumorigenesis and tumor progression in several solid cancers. However, little is known about the expression and prognostic value of miR-96 in acute myeloid leukemia (AML). Therefore, the aim of this study was to investigate the correlation of miR-96 expression with clinicopathological features and prognosis of AML.
Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-96 in mononuclear cells from bone marrow or peripheral blood specimens in 86 patients with newly diagnosed AML.
Compared with normal controls, miR-96 expression was significantly downregulated in patients with newly diagnosed AML (P < 0.001). In analysis of 14 diagnosis/CR-paired samples, the expression level of miR-96 was found markedly elevated in patients after treatment than before (P < 0.001). Moreover, lower levels of miR-96 were associated with a higher white blood cell count, bone marrow blast count (P < 0.001 and 0.022, respectively), and lower hemoglobin and platelet count (P = 0.036 and 0.033, respectively). Although the low-expression group seemed to have a lower CR rate (53.85% vs 70.0%), there was no significant difference between the two groups (P = 0.213). The low-expression group had a lower relapse-free survival (RFS) (P = 0.038) and overall survival (OS) (P = 0.022) compared with the high-expression group during a median follow-up of 20 months.
Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1434808553949498.
miRNA（miR）-96 的异常表达与几种实体瘤的肿瘤发生和肿瘤进展有关。然而，miR-96 在急性髓系白血病（AML）中的表达和预后价值知之甚少。因此，本研究旨在探讨 miR-96 表达与 AML 临床病理特征和预后的相关性。
采用实时定量 RT-PCR 法检测 86 例初诊 AML 患者骨髓或外周血单个核细胞中 miR-96 的表达水平。
与正常对照组相比，初诊 AML 患者 miR-96 表达明显下调（P<0.001）。在 14 例诊断/缓解配对样本分析中，治疗后患者 miR-96 表达水平明显高于治疗前（P<0.001）。此外，miR-96 水平较低与白细胞计数较高、骨髓原始细胞计数较高（分别为 P<0.001 和 0.022）、血红蛋白和血小板计数较低（分别为 P=0.036 和 0.033）有关。虽然低表达组的 CR 率似乎较低（53.85%比 70.0%），但两组间无显著差异（P=0.213）。在中位随访 20 个月期间，低表达组的无复发生存率（RFS）（P=0.038）和总生存率（OS）（P=0.022）均低于高表达组。
本研究数据表明，miR-96 在初诊 AML 患者中表达下调，与白血病负荷以及 RFS 和 OS 相关。这表明 miR-96 检测可能成为 AML 预后和监测的潜在生物标志物。
